For patients and members of the public: Our Range

Medicine Range - S

Our range of generic and branded medicines and medical devices includes prescription medicines used in primary and secondary care and covers a broad range of therapeutic areas.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

To contact Teva's Medical Information Service email: medinfo@tevauk.com or telephone: 0207 540 7117.

To contact Customer Services about the supply and availability of a medicine email: customer.services@tevauk.com or telephone: 0800 590 502.

Available as
  • Inhaler
  • Nebuliser Solution
Available as
  • Dry Powder Inhaler
Available as
  • Soluble Tablets
Available as
  • Film-coated Tablets
Available as
  • Inhalation Vapour
Available as
  • Film-coated Tablets
Available as
  • Chewable Tablets
  • Oral Liquid
  • Soft Capsules
Available as
  • Film-coated Tablets
Available as
  • Capsules
  • Chewable Tablets
  • Granules for Solution
Available as
  • Granules for Solution
Available as
  • Nebuliser Solution
Available as
  • Granules for Solution
Available as
  • Film-coated Tablets
Available as
  • Film-coated Tablets
Available as
  • Tablets
Available as
  • Film-coated Tablets

For patients taking a Teva medicine: Reporting of side effects - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the Package Leaflet. Side effects can be reported to Teva using the Reporting Side Effects Form or email uk.safety@tevauk.com or also directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of a medicine.


Medicines showing this symbol are subject to additional monitoring. This will allow quick identification of new safety information. For patients taking a Teva medicine: You can help by reporting any side effects experienced. See Yellow Card Scheme for how to report side effects, or report to Teva by using the contact points above.

Date of preparation: December 2021
Reference: COB-GB-NP-00077

Date of preparation: December 2021
Reference: COB-GB-00006